Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy
Angiotensin II receptor antagonists (angiotensin II receptor blockers; ARBs) are a class of antihypertensive drugs that are generally considered comparable to ACE inhibitors in the prevention of heart and kidney failure. However, these two classes of agents do interfere in different stages of the renin-angiotensin system. In patients with type 2 diabetes mellitus, advantages for ARBs over conventional (non-ACE inhibitor) therapy on progression from micro- to macroalbuminuria and overt nephropathy and end-stage renal disease have been shown in clinical trials. In patients with type 2 diabetes and end-stage renal disease, the need for dialysis and/or transplantation results in the use of major healthcare resources. This paper reviews the available economic evidence on treatment with ARBs in type 2 diabetic patients with advanced renal disease.
Within-trial analytic and Markov model economic evaluations of the RENAAL (Reduction of Endpoint in Non-insulin dependent diabetes mellitus with Angiotensin II Antagonist Losartan), IDNT (Irbesartan Diabetic Nephropathy Trial) and IRMA (IRbesartan in type 2 diabetes with MicroAlbuminuria)-2 studies suggest that treatment with ARBs in patients with type 2 diabetes with overt or incipient nephropathy confers health gains and net cost savings compared with conventional (non-ACE inhibitor) therapy. For reimbursement and reference pricing decisions, there is a need for a head-to-head comparison of an ACE inhibitor with ARBs to model all possible costs and effects of ACE inhibitors and ARBs. This will result in a proper pharmacoeconomic outcome, where both types of drugs can be compared for healthcare decisions.
KeywordsDiabetic Nephropathy Losartan Amlodipine Valsartan Telmisartan
All authors participated in the concept and design of the paper; analysis and interpretation of data; drafting or revision of the manuscript. The authors have no conflicts of interest to declare.
The authors acknowledge the work of G.W. Carides and W.C. Gerth (Merck & Company, Blue Bell, Pennsylvania, USA) on adapting the RENAAL trial-based pharmacoeconomic model for losartan to the Dutch situation. M.J. Postma and L.J.P. Annemans previously received grant support for economically evaluating ARBs by MSD (Haarlem, The Netherlands), and Sanofi-Synthelabo (Paris, France), respectively.
No sources of funding were used to assist in the preparation of this study.
- 9.van Hout B, Simeon GP, McDonnell J, et al. Economic evaluation of benazepril in chronic renal insufficiency. Kidney Int 1997; 52 (63): S159–S162Google Scholar
- 10.van Ballegooie E, van Everdingen JJE. CBO guidelines on diagnosis, treatment, and prevention of complication in diabetes mellitus, retinopathy, foot ulcers, nephropathy and cardiovascular diseases: Dutch Institute for Quality Assurance [in Dutch]. Nederlands Tijdschrift voor Geneeskunde 2000; 144 (9), 413–418PubMedGoogle Scholar
- 12.Palmer AJ, Annemans L, Roze S, et al. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transplant 2003; 18: 2059–2066PubMedCrossRefGoogle Scholar
- 13.USRDS annual data report 2004. Bethesda (MD): National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases, 2004Google Scholar
- 28.Data on file, Merck & Co., Inc. 2003Google Scholar
- 34.Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicenter trial (the EUROPA study). The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Lancet 2003; 362: 782–788PubMedCrossRefGoogle Scholar
- 41.International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Pharmacoeconomic guidelines around the world [online]. Available from URL: http://www.ispor.org/PEguidelines/index.asp [Accessed 2005 Jun 30]Google Scholar
- 43.Postma MJ, Bartstra J, Annemans LJP. Angiotensin-II antagonists in diabetes mellitus type 2 [in Dutch]. Pharm Weekbl 2004; 139 (33): 1060–1063Google Scholar
- 46.Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004; 27: 1897–1903PubMedCrossRefGoogle Scholar
- 48.Gold MR, Siegel JE, Russel LB, et al., editors. Cost-effectiveness in health and medicine. New York: University Press, 1996Google Scholar
- 51.College voor zorgverzekeringen (CVZ). Guidelines for pharmacoeconomic research [in Dutch]. Amstelveen: College voor zorgverzekeringen, 1999Google Scholar
- 55.Palmer AJ, Roze S, Valentine WJ, et al. Irbesartan is projected to be cost and life saving compared to standard blood pressure control alone for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria in Spanish, Swedish and Swiss settings [abstract]. Value Health 2004; 7 (6): 655CrossRefGoogle Scholar
- 60.Schädlich PK, Brecht JG, Rangoonwala B, et al. Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the statutory health insurance perspective. Pharmacoeconomics 2004; 22 (15), 955–973PubMedCrossRefGoogle Scholar
- 67.Atthobari J, Asselbergs FW, Boersma C, et al. Cost-effectiveness of screening for albuminuria and subsequent treatment with ACE-inhibitor to prevent cardiovascular events: a pharmacoeconomic analysis linked to the PREVEND and PREVEND-IT studies. The PREVEND-IT study group. Clin Ther 2006; 28 (3): 432–444PubMedCrossRefGoogle Scholar